Faron Pharmaceuticals Oy appointed Juhana Heinonen chief commercial officer, effective January 2018.
Heinonen was previously the global marketing director of AstraZeneca PLC's asthma biologic Fasenra.
At Faron, Heinonen will work on the commercialization strategy for the company's lead candidate, Traumakine, which is in stage phase 3 trials for treating acute respiratory distress syndrome.
